DE69602756D1 - Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie - Google Patents

Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie

Info

Publication number: DE69602756D1
Authority: DE; Germany
Prior art keywords: present; methods; adrenomedullin; physiology; peptides
Prior art date: 1995-08-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69602756T

Other languages

English (en)

Other versions

DE69602756T2 (de

Inventor

Frank Cuttitta

Alfredo Martinez

Mae Miller

Edward Unsworth

William Hook

Thomas Walsh

Karen Gray

Charles Macri

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

US Department of Health and Human Services

Original Assignee

US Department of Health and Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-18

Filing date

1996-08-16

Publication date

1999-07-08

1996-08-16 Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services

1999-07-08 Publication of DE69602756D1 publication Critical patent/DE69602756D1/de

2000-02-10 Application granted granted Critical

2000-02-10 Publication of DE69602756T2 publication Critical patent/DE69602756T2/de

2016-08-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

102000004379 Adrenomedullin Human genes 0.000 title abstract 11
101800004616 Adrenomedullin Proteins 0.000 title abstract 11
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title abstract 9
230000035479 physiological effects, processes and functions Effects 0.000 title abstract 2
102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 title 1
101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 title 1
PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 title 1
230000007170 pathology Effects 0.000 title 1
238000000034 method Methods 0.000 abstract 5
230000003914 insulin secretion Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
230000003305 autocrine Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
231100000673 dose–response relationship Toxicity 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

DE69602756T 1995-08-18 1996-08-16 Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie Expired - Lifetime DE69602756T2 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US251495P	1995-08-18	1995-08-18
US293695P	1995-08-30	1995-08-30
US1317296P	1996-03-12	1996-03-12
PCT/US1996/013286 WO1997007214A1 (en)	1995-08-18	1996-08-16	Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Publications (2)

Publication Number	Publication Date
DE69602756D1 true DE69602756D1 (de)	1999-07-08
DE69602756T2 DE69602756T2 (de)	2000-02-10

Family

ID=27357180

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69602756T Expired - Lifetime DE69602756T2 (de)	1995-08-18	1996-08-16	Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie

Country Status (7)

Country	Link
US (4)	US6320022B1 (de)
EP (1)	EP0845036B1 (de)
JP (2)	JPH11512087A (de)
AT (1)	ATE180832T1 (de)
CA (1)	CA2229741C (de)
DE (1)	DE69602756T2 (de)
WO (1)	WO1997007214A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6440421B1 (en)	1996-04-18	2002-08-27	Auchkland Uniservices Limited	Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) *	1996-04-18	1999-03-30	Auckland Uniservices Limited	Treatment of bone disorders with adrenomedullin
WO1999016406A2 (en) *	1997-09-26	1999-04-08	Auckland Uniservices Limited	Therapeutic method
WO2001018550A2 (en)	1999-09-10	2001-03-15	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Determination of adrenomedullin-binding proteins
WO2002040571A1 (en) *	2000-11-17	2002-05-23	Lee Jin Kyu	Poly (methylsilsesquioxane) copolymers and preparation method thereof
FR2821080B1 (fr) *	2001-02-20	2003-12-19	Sanofi Synthelabo	Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
US20110087312A1 (en) *	2001-03-02	2011-04-14	Erchonia Corporatin	Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy
CA2441228A1 (en)	2001-03-23	2002-10-03	Aphton Corporation	Combination treatment of pancreatic cancer
US20090191232A1 (en)	2001-05-04	2009-07-30	Gevas Philip C	Combination therapy for the treatment of tumors
CA2481399A1 (en) *	2002-03-19	2003-09-25	Oncorex, Inc.	Peptides and pharmaceutical compositions comprising said peptides for treating cancer
US20040127445A1 (en) *	2002-08-28	2004-07-01	Chondrogene Limited	Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
AU2003249012A1 (en) *	2002-09-30	2004-04-23	Japan As Represented By The President Of The University Of Tokyo	Genes and polypeptides relating to human myeloid leukemia
WO2004028352A2 (en) *	2002-09-30	2004-04-08	Bayer Pharmaceuticals Corporation	Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1545287B1 (de) *	2002-10-04	2012-12-05	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES	Vasoregulierende verbindungen und anwendungsverfahren
US7462593B2 (en)	2002-11-07	2008-12-09	Us Gov Health & Human Serv	Compositions and methods for promoting angiogenesis
CA2520010C (en)	2003-03-28	2012-07-10	Aphton Corporation	Gastrin hormone immunoassays
US7228658B2 (en)	2003-08-27	2007-06-12	Weyerhaeuser Company	Method of attaching an end seal to manufactured seeds
US20080249115A1 (en) *	2003-09-08	2008-10-09	The Government Of The United States Of America, As	Non Peptide Agonists and Antagonists of Adrenomedullin and Gastric Releasing Peptide
US8691575B2 (en) *	2003-09-30	2014-04-08	Weyerhaeuser Nr Company	General method of classifying plant embryos using a generalized Lorenz-Bayes classifier
CA2486289C (en) *	2003-11-25	2008-01-08	Weyerhaeuser Company	Combination end seal and restraint
US20050108935A1 (en) *	2003-11-25	2005-05-26	Edwin Hirahara	Method and system of manufacturing artificial seed coats
CA2484533C (en) *	2003-11-25	2008-12-02	Weyerhaeuser Company	Systems and method of embryo delivery for manufactured seeds
US20050108929A1 (en) *	2003-11-25	2005-05-26	Edwin Hirahara	Method and system for creating manufactured seeds
US7555865B2 (en) *	2003-11-25	2009-07-07	Weyerhaeuser Nr Company	Method and system of manufacturing artificial seed coats
US7356965B2 (en) *	2003-12-11	2008-04-15	Weyerhaeuser Co.	Multi-embryo manufactured seed
US7591287B2 (en) *	2003-12-18	2009-09-22	Weyerhaeuser Nr Company	System and method for filling a seedcoat with a liquid to a selected level
US7568309B2 (en) *	2004-06-30	2009-08-04	Weyerhaeuser Nr Company	Method and system for producing manufactured seeds
CA2580965C (en)	2004-09-22	2014-04-08	Receptor Biologix, Inc.	Monoclonal antibodies to progastrin
CA2518166C (en) *	2004-09-27	2012-02-21	Weyerhaeuser Company	Manufactured seed having a live end seal
CA2518279A1 (en) *	2004-09-27	2006-03-27	Weyerhaeuser Company	Manufactured seed having a live end seal coating
US7547488B2 (en) *	2004-12-15	2009-06-16	Weyerhaeuser Nr Company	Oriented strand board panel having improved strand alignment and a method for making the same
US7654037B2 (en) *	2005-06-30	2010-02-02	Weyerhaeuser Nr Company	Method to improve plant somatic embryo germination from manufactured seed
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US9829494B2 (en) *	2005-12-01	2017-11-28	Adrenomed Ag	Methods of treatment using ADM antibodies
US8906857B2 (en) *	2005-12-01	2014-12-09	B.R.A.H.M.S. Gmbh	Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
DE102006052916A1 (de) *	2006-11-08	2008-05-15	Brahms Aktiengesellschaft	Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
WO2009043481A2 (en) *	2007-09-11	2009-04-09	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
FR2934597B1 (fr) *	2008-07-31	2013-04-19	Univ Aix Marseille Ii	Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
CN102203607A (zh) *	2008-10-31	2011-09-28	B.R.A.H.M.S有限公司	根据对心血管系统的影响将食物和/或饮料和/或饮食和/或营养疗法和/或药物进行分类的方法和测定方法
NZ628987A (en)	2009-02-03	2015-11-27	Amunix Operating Inc	Extended recombinant polypeptides and compositions comprising same
EP2389799A1 (de) *	2010-05-25	2011-11-30	BioMass Booster, S.L.	Verfahren zur Erhöhung von Pflanzenbiomasse
CN103109192A (zh) *	2010-06-18	2013-05-15	塞尚公司	用于妊娠性高血压和先兆子痫的预后和风险评估的标志物
FR2964103B1 (fr) *	2010-08-30	2018-11-23	Universite D'aix-Marseille	Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
JP5932279B2 (ja) *	2011-10-07	2016-06-08	ポーラ化成工業株式会社	スクリーニング方法
US8776012B2 (en) *	2011-10-25	2014-07-08	International Business Machines Corporation	Automatic scheduling of review meetings
SG10201801919QA (en)	2011-11-16	2018-04-27	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
JP6224608B2 (ja)	2011-11-16	2017-11-01	アドレノメトアクチェンゲゼルシャフト	血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
ES2617211T3 (es) *	2011-11-16	2017-06-15	Sphingotec Gmbh	Ensayos de adrenomedulina y métodos para determinar la adrenomedulina madura
SG10201802054TA (en)	2011-11-16	2018-05-30	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
JP5953108B2 (ja) *	2012-05-14	2016-07-20	ポーラ化成工業株式会社	スクリーニング方法
EP2905029B1 (de) *	2012-10-04	2018-11-21	Shionogi&Co., Ltd.	Arzneimittel zur hemmung von tumormetastasen
JP6673847B2 (ja)	2013-12-20	2020-03-25	アンギオビオメトゲゼルシャフトミットベシュレンクテルハフツング	癌治療に使用するためのアドレノメデュリンバインダー
DK3067093T3 (da) *	2015-03-12	2019-11-18	Fund Rioja Salud	Anvendelse af en inhibitor af adrenomedullin til fremstilling af et lægemiddel egnet til forebyggelse og behandling af sygdomme, der reducerer knogletætheden
WO2018213934A1 (en)	2017-05-26	2018-11-29	The Governors Of The University Of Alberta	Self-assembling peptide for activating human mast cells
EP3624841A4 (de)	2017-06-15	2021-01-27	Cancer Advances, Inc.,	Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs
EP3438668A1 (de) *	2017-08-04	2019-02-06	B.R.A.H.M.S GmbH	Diagnose und risikostratifizierung von pilzinfektionen
EP3971573A1 (de)	2017-09-13	2022-03-23	B.R.A.H.M.S GmbH	Proadrenomedullin als marker für anormale thrombozytenspiegel
MX2022005676A (es)	2019-11-13	2022-10-27	Amunix Pharmaceuticals Inc	Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2193143T3 (es) *	1992-03-05	2003-11-01	Univ Texas	Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
AU6770794A (en)	1993-04-23	1994-11-21	Herbert J. Evans	Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
JP2774769B2 (ja)	1993-04-26	1998-07-09	賢治寒川	アドレノメデュリン

1996
- 1996-08-16 EP EP96928205A patent/EP0845036B1/de not_active Expired - Lifetime
- 1996-08-16 CA CA2229741A patent/CA2229741C/en not_active Expired - Fee Related
- 1996-08-16 JP JP9509499A patent/JPH11512087A/ja not_active Withdrawn
- 1996-08-16 WO PCT/US1996/013286 patent/WO1997007214A1/en active IP Right Grant
- 1996-08-16 AT AT96928205T patent/ATE180832T1/de not_active IP Right Cessation
- 1996-08-16 DE DE69602756T patent/DE69602756T2/de not_active Expired - Lifetime
- 1996-08-16 US US09/011,922 patent/US6320022B1/en not_active Expired - Lifetime
2001
- 2001-08-16 US US09/931,700 patent/US7101548B2/en not_active Expired - Fee Related
2006
- 2006-09-05 US US11/517,599 patent/US7622272B2/en not_active Expired - Fee Related
- 2006-12-26 JP JP2006349430A patent/JP4077861B2/ja not_active Expired - Fee Related
2009
- 2009-09-29 US US12/569,821 patent/US7939639B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20100021469A1 (en)	2010-01-28
AU6776596A (en)	1997-03-12
US7622272B2 (en)	2009-11-24
ATE180832T1 (de)	1999-06-15
CA2229741A1 (en)	1997-02-27
US7101548B2 (en)	2006-09-05
EP0845036B1 (de)	1999-06-02
WO1997007214A1 (en)	1997-02-27
US6320022B1 (en)	2001-11-20
CA2229741C (en)	2012-05-08
EP0845036A1 (de)	1998-06-03
US20070004630A1 (en)	2007-01-04
US7939639B2 (en)	2011-05-10
JPH11512087A (ja)	1999-10-19
DE69602756T2 (de)	2000-02-10
JP2007145850A (ja)	2007-06-14
AU710662B2 (en)	1999-09-23
JP4077861B2 (ja)	2008-04-23
US20020055615A1 (en)	2002-05-09

Legal Events

Date	Code	Title	Description
2000-06-29	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE69602756D1 (de)	1999-07-08	Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
RU95108231A (ru)	1997-03-20	Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
Baluna et al.	1999	Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
ES2227527T3 (es)	2005-04-01	Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
DE69433820D1 (de)	2004-07-01	Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
SE9401406D0 (sv)	1994-04-25	Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE152910T1 (de)	1997-05-15	Verwendung von taxol zur herstellung eines arzneimittels zur behandlung von krebs
NZ504549A (en)	2002-12-20	Use of a modified non-toxic botulinum toxin for delivery of medicines where non-toxicity results from modification of light chain holotoxin to eliminate zinc-dependant metalloendoprotease without modification to the heavy chain portion essential for translocation activity from the gut to the lumen
ES2123662T3 (es)	1999-01-16	Derivados de mostaza nitrogenada enlazada a aminoacidos y su uso como profarmacos en el tratamiento de tumores.
JP2011517319A5 (de)	2012-04-19
DE69425246T2 (de)	2001-01-04	Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
ATE332702T1 (de)	2006-08-15	Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE59004445D1 (de)	1994-03-10	Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen.
DE69836139D1 (de)	2006-11-23	Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
AU6682598A (en)	1998-09-22	Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
HK1014498A1 (en)	1999-09-30	Bpi-protein-products for depressed reticuloendothelial system function.
DE59610251D1 (de)	2003-04-24	Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
NO922621L (no)	1992-09-02	Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
Rhodes	1980	Resistance of tumour cells to macrophages: A short review
DE69630682D1 (de)	2003-12-18	Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
DE69131517T2 (de)	2000-01-13	Verwendung von Prostaglandin-E1 zur Behandlung männlicher erektiler Impotenz
WO1999042127A3 (en)	1999-10-28	Receptor derived peptides as modulators of receptor activity
ATE194076T1 (de)	2000-07-15	Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69420574T2 (de)	2000-05-04	Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
ES2135145T3 (es)	1999-10-16	2-ciano-3-mercaptocrotonamidas.